Abstract:BackgroundAlanine transaminase (ALT) and aspartate aminotransferase (AST) are referred to as liver transaminases. Although used routinely in clinical practice for decades, their role as predictors of mortality has not been examined until recently. We studied the predictive value of these serum transaminases in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).MethodsWe analyzed records of 2417 consecutive STEMI patients with no preexisting liver disease who were treated with primary PCI at the Cardiovascular Center in the First Hospital of Jilin University. The outcomes measured were all-cause mortality at the first month and at 2 years. The relationship between the baseline serum transaminase levels and primary outcome was determined.ResultsWe found a significant correlation between elevated liver transaminases and the Killip classification (P < 0.001 for ALT; P < 0.001 for AST), cardiac troponin I (P = 0.002 for ALT; P < 0.001 for AST), infarct-related coronary artery (P = 0.036 for ALT; P = 0.011 for AST), and pre-thrombolysis-in-myocardial-infarction (pre-TIMI) flow (P < 0.001 for ALT and AST). The serum level of ALT and AST were high along with the increasing of the grade of Killip classification. The primary infarct-related coronary artery in patients with ALT ≥95th percentage was left anterior descending artery (56%), followed by right coronary artery (36%). The OR for all-cause mortality at 2 years for participants with ALT ≥95th percentage was 5.370 (95% CI: 2.899–9.948), 7.034 (95% CI: 3.718–13.307) after adjustment for age and gender and 1.051 (95% CI: 0.302–3.652) after adjustment for all covariables. The OR for all-cause mortality at 2 years for participants with AST ≥95th percentage was 5.370 (95% CI 2.899–9.948) and 5.699 (95% CI 3.030–10.718) after adjustment for age and gender and 1.796 (95% CI: 0.588–5.481) after adjustment for all covariables. ALT (HR 1.004, 95% CI 1.001–1.006, P = 0.010) and AST (HR 0.999, 95% CI 0.998–1.000, P = 0.030) were associated with early all-cause mortality in patients with STEMI treated with PCI but not at 2 years post-procedure, unless for AST and ALT levels ≥95th percentage. Moreover, short- and long-term outcomes were significantly worse when both AST and ALT levels ≥95th percentage (P < 0.001).ConclusionsSerum transaminases ≥95th percentage were associated with a significantly increased incidence of short- and long-term all-cause mortality.Trial registrationRegistration number: ChiCTR-EPC-16008199, 31 March 2016.

Elevated Liver Enzymes and Cardiovascular Mortality: a Systematic Review and Dose–response Meta-Analysis of More Than One Million Participants

Elevated Serum Alanine Aminotransferase and γ-Glutamyltransferase and Mortality in the United States Population

Association Between Serum Uric Acid Levels and Long-Term Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease: a Nationwide Cohort Study

Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Associations of serum alkaline phosphatase level with all-cause and cardiovascular mortality in the general population

The Association between Liver Enzymes and Mortality Stratified by Non-Alcoholic Fatty Liver Disease: An Analysis of NHANES III

Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants

Associations between serum levels of liver function biomarkers and all-cause and cause-specific mortality: a prospective cohort study

Serum liver enzymes and risk of stroke: Systematic review with meta‐analyses and Mendelian randomization studies

Association of serum transaminases with short- and long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Gut microbiota metabolites and risk of major adverse cardiovascular events and death: A systematic review and meta-analysis

Liver Enzymes Mediate the Association Between Aldehydes Co-Exposure and Hypertriglyceridemia

Associations between Liver Enzymes, Lifestyle Risk Factors and Pre-Existing Medical Conditions in a Population-Based Cross-Sectional Sample

Association of gamma‐glutamyl transferase concentrations with all‐cause and cause‐specific mortality in Chinese adults with type 2 diabetes

The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment

Association between liver enzymes and type 2 diabetes: a real-world study

Serum Transaminases And Older Adults: Distribution And Associations With All-Cause Mortality

Lower Alanine Aminotransferase Levels Are Associated with Increased All-Cause and Cardiovascular Mortality in Nonalcoholic Fatty Liver Patients.

Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

High Alkaline Phosphatase and Low Intact Parathyroid Hormone Associate with Worse Clinical Outcome in Peritoneal Dialysis Patients

Cross-sectional and Longitudinal Association of Serum Alanine Aminotransaminase and Γ-Glutamyltransferase with Metabolic Syndrome in Middle-Aged and Elderly Chinese People.